Ebola Precaution: UK Aid Worker Isolated in London After DRC Exposure
Ebola Precaution: UK Aid Worker Isolated in London After DRC Exposure
A UK humanitarian worker is under observation in a London hospital following potential Ebola exposure in the DRC. Authorities assure low risk to the public. Get the full story.
A humanitarian worker, a UK resident, is currently under observation in a London hospital following a potential exposure to Ebola. This individual had been working with a humanitarian organization in the Democratic Republic of Congo (DRC), actively supporting the response to an ongoing Ebola outbreak in the region.
While the worker is reportedly not displaying any symptoms and appears well, the decision was made to evacuate them from the DRC on a flight chartered specifically for this precautionary measure. This proactive step aims to ensure the highest level of safety and monitoring given the nature of the potential exposure.
Upon arrival in London, the individual was immediately placed in isolation and is being assessed and monitored by infectious disease specialists at an undisclosed hospital. They are expected to remain in isolation throughout the entire potential incubation period for Ebola, which can range from two to 21 days. The UK Health Security Agency (UKHSA) collaborates with international partners to facilitate the safe return and care of British residents at risk of Ebola.
Richard Pebody, director of epidemic and emerging infections at UKHSA, has reassured the public, stating, "The risk to the general public remains low. This individual has been transferred out of an abundance of caution, and we’re pleased they remain well." Currently, there are no confirmed cases of Ebola in the UK.
The ongoing Ebola outbreak in the DRC and Uganda involves the Bundibugyo variation of the virus. The World Health Organization recently reported 2,423 confirmed cases of Ebola, 967 confirmed deaths, and 252 suspected cases. A significant challenge in controlling this variant is the current lack of a specific vaccine or treatment, although the University of Oxford is set to begin human trials for a new jab that could be available within weeks.
